NeoClinical Launches Neo PayPerPatient Solution for Asia-Pac
NeoClinical™, the leading digital clinical trial recruitment agency for Australia, New Zealand and Asian markets todayofficially launched its latest recruitment product, Neo PayPerPatient click here.
Neo PayPerPatient has emerged from 6 months of beta testing, including regulatory compliance, and integration of some of the latest online consumer engagement software and tools. Neo PayPerPatient has already built powerful databases of people wanting more information about the latest clinical trials for conditions including gout, arthritis, Alzheimer’s, menopause, diabetes, prostate cancer and asthma.
Neo PayPerPatient is a risk share pay-as-you-go solution for new studies or current studies that are underperforming and need a boost to recruitment. Sponsors only pay a nominal fee for partially screened patients then a moderate fee for those that proceed to full enrolment. NeoClinical™ manages all the rest. NeoClinical™‘s advertising and PR expertise as well as the team’s considerable online and social media experience to deliver results for clients. NeoClinical™ study recruitment campaigns feature innovative and EC compliant advertising, public relations and online content marketing campaigns.
NeoClinical™ typically achieves referral conversion rates of 40-60% and recently achieved a 63% conversion rate for a New Zealand Study.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
